Form 8-K Galena Biopharma, Inc. For: Nov 09

Go back to Form 8-K Galena Biopharma, Inc. For: Nov 09

Roth Trims PT on Galena (GALE) Following Q3 Results, Plans to Spin Commercial Assets

November 10, 2015 9:18 AM EST

Roth Capital is trimming its price target on Buy-rated Galena Biopharma (Nasdaq: GALE) from $8 to $6 following Q3 results and plans to spin its commercial business, as... More